Une candidature conçue pour ce poste — un CV et une lettre de motivation personnalisés qui correspondent à l’offre.
AstraZeneca in Gaithersburg, MD, seeks the Lead/Head of USMA Business Planning, a senior strategic role driving the integrated USMA planning cycle (iMAP) and shaping how the organization plans, prioritizes and executes against enterprise strategy.
You will own the portfolio, lead the iMAP forums, set agendas and milestones, and partner with the CIME Innovation team to build a future‑fit, AI‑enabled organization.
Location: Gaithersburg, MD (3 days per week)
The Lead/Head, USMA Business Planning is a senior strategic leadership role that owns and drives the broader finance and planning cycle for US Medical Affairs (USMA), shaping how the organization plans, prioritizes and executes against enterprise strategy. The role owns the integrated USMA business planning capability (iMAP) – unifying strategy, medical plans, initiatives, resources, budgets, payments and milestones into a single operating model – and gives CIME and USMA leadership one consolidated, decision-ready view of the portfolio and the actions required to advance it. Working directly with the Finance Director, the Lead/Head coordinates the key forums that govern the USMA planning cycle — including the franchise forums — and independently owns the agendas, milestones, timelines, due dates and organizational scorecard that keep USMA aligned and on track. The Lead/Head builds and leads a future‑fit, AI‑enabled SPM and Business Specialist organization in partnership with the CIME Innovation team, and works as a trusted strategic partner to the Head of CIME, the USMA Vice President, Franchise Heads, the Finance Director, Commercial OLT Business Planning Leads and GMA MESO leadership. This is an elevated, enterprise‑facing role that combines strategic influence, senior people leadership and hands‑on portfolio ownership across a complex, matrixed medical organization — with the expectation that the Lead/Head independently leads the USMA finance and planning cycle and the integrated medical planning process end‑to‑end, rather than simply supporting it.